NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-mrna/ to learn more.

The investigation concerns whether Moderna and certain of its officers and/or directors have engaged in fraud, negligence or other unlawful business practices.

On May 19, 2020, media outlets reported that vaccine experts had lodged criticism at the research intended to support the Company’s coronavirus vaccine candidate, based on insufficient data.

On this news, the price of Moderna’s shares plummeted over 20%, on heavier than average trading volume.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

Click to expand...

It's possible there's no actual production of antibodies, in which because either the mRNA didn't get into the cells, the cells didn't make the proteins from the mRNA or the immune system didn't recognize those proteins ... or the dose was too low," Dr. Evan Anderson, the lead investigator of the Moderna vaccine study at Emory University where part of the human trial is taking place, told CNN's Gupta in a recent interview.
Anderson added that there is a "theoretical possibility" that the vaccine could trigger an "enhanced immune response" that actually worsens the illness.
Jason Schrum, a founding scientist at Moderna, also pointed out that the vaccine formulation listed on Moderna's clinical trial page for Covid-19 doesn't seem to include a key element to conjure a strong efficacy in any vaccine: the adjuvants.
Adjuvants stimulate the body's immune system to react to the vaccine antigen -- the molecules that trigger an immune response in the body. In other words, they boost the body's immune response.
"Typically, what you see in any vaccine if they use adjuvants, they clearly identify that and say this is the purpose of using in the vaccine formulation as an adjuvant," said Schrum, who is no longer with the company. "In that one [Moderna], I just don't see that."
Moderna confirmed that it is not using an adjuvant.'

Click to expand...

Specter said:

In case anyone's decisions were based on the post I shared from an insider I feel kinda responsible so I just post this here to look out for others but the fun might be over with Moderna. Time to cash out? if not just be careful from now on.

Otherwise this is some informative news as well

https://www.cnbc.com/2020/05/18/moderna-plans-to-issue-1point25-billion-in-fresh-equity-following-20percent-stock-jump.html

This basically means the whole show could've been a pump & dump from day 1, there are investigations going into this too.
https://www.businesswire.com/news/home/20200519006005/en/MODERNA-INVESTIGATION-INITIATED-Louisiana-Attorney-General-Kahn

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-mrna/ to learn more.

The investigation concerns whether Moderna and certain of its officers and/or directors have engaged in fraud, negligence or other unlawful business practices.

On May 19, 2020, media outlets reported that vaccine experts had lodged criticism at the research intended to support the Company’s coronavirus vaccine candidate, based on insufficient data.

On this news, the price of Moderna’s shares plummeted over 20%, on heavier than average trading volume.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

Click to expand...

https://markets.businessinsider.com/news/stocks/moderna-stock-price-target-raised-goldman-sachs-coronavirus-drug-results-2020-5-1029212025
Goldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed "encouraging" results.

Never trust a kike, when these kikes encourage things like this there are very ulterior motives. He's screwed people over with their money before and remained untouched, he can do so again. He's squeezing out the last juice so he can hit home.

It's possible there's no actual production of antibodies, in which because either the mRNA didn't get into the cells, the cells didn't make the proteins from the mRNA or the immune system didn't recognize those proteins ... or the dose was too low," Dr. Evan Anderson, the lead investigator of the Moderna vaccine study at Emory University where part of the human trial is taking place, told CNN's Gupta in a recent interview.
Anderson added that there is a "theoretical possibility" that the vaccine could trigger an "enhanced immune response" that actually worsens the illness.
Jason Schrum, a founding scientist at Moderna, also pointed out that the vaccine formulation listed on Moderna's clinical trial page for Covid-19 doesn't seem to include a key element to conjure a strong efficacy in any vaccine: the adjuvants.
Adjuvants stimulate the body's immune system to react to the vaccine antigen -- the molecules that trigger an immune response in the body. In other words, they boost the body's immune response.
"Typically, what you see in any vaccine if they use adjuvants, they clearly identify that and say this is the purpose of using in the vaccine formulation as an adjuvant," said Schrum, who is no longer with the company. "In that one [Moderna], I just don't see that."
Moderna confirmed that it is not using an adjuvant.'

Click to expand...

Could this explain their CEO dumping shares at $80? The CMO is selling shares. And the CFO is leaving in August. Without having insiders it's very hard to make gains like those at the top of the pyramid, you have to study very closely on what they do. There could possibly be a buyback potential for a much cheaper price but it'd be best to wait for further results at this point. There are better vaccine stocks out there.

For anyone who made big gains so far happy payday!

Click to expand...